Vanguard Personalized Indexing Management’s Nektar Therapeutics NKTR Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$292K	Buy	4,182 +497	+13%	+$36.4K	﹤0.01%	1717
2026 Q1	$265K	Buy	+3,685	New	+$210K	﹤0.01%	1675
2025 Q4	–	Sell	-3,911	Closed	-$223K	–	2040
2025 Q3	$223K	Buy	+3,911	New	+$129K	﹤0.01%	1641
2025 Q2	–	Sell	-2,458	Closed	-$25.1K	–	2005
2025 Q1	$25.1K	Buy	2,458 +1,335	+119%	+$17.4K	﹤0.01%	1750
2024 Q4	$15.7K	Buy	1,123 +261	+30%	+$4.6K	﹤0.01%	1783
2024 Q3	$16.8K	Buy	862 +6	+0.7%	+$114	﹤0.01%	1741
2024 Q2	$15.9K	Buy	856 +65	+8%	+$1.37K	﹤0.01%	1671
2024 Q1	$11.1K	Buy	+791	New	+$8.28K	﹤0.01%	1619
2023 Q4	–	Sell	-2,572	Closed	-$23K	–	1611
2023 Q3	$23K	Buy	+2,572	New	+$24.8K	﹤0.01%	1449

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Personalized Indexing Management's NKTR Position: Q2 2026 in Review

Vanguard Personalized Indexing Management increased its Nektar Therapeutics (NKTR) stake by 13% in Q2 2026, buying an estimated $36.4K and bringing the position to 4,182 shares worth $292K. The position accounts for ﹤0.01% of the portfolio, ranked #1717.

Vanguard Personalized Indexing Management first reported a position in NKTR in Q3 2023 and has held it in 9 quarters since. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

Vanguard Personalized Indexing Management held 4,182 shares of Nektar Therapeutics worth $292K as of Q2 2026.
Vanguard Personalized Indexing Management bought 497 Nektar Therapeutics shares in Q2 2026, an estimated $36.4K.
Nektar Therapeutics made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #1717 holding.
Vanguard Personalized Indexing Management first reported a position in Nektar Therapeutics in Q3 2023 and has held it in 9 quarters since.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.